Additional file 1 of Immune cell phenotypes and mortality in the Framingham Heart Study

Additional file 1: Table 1. Descriptive statistics for the immune cell phenotypes and IL-6. Table 2. Associations between immune cell phenotypes or IL-6 and mortality (adjusted for age, sex and CMV status). Table 3. Associations between immune cell phenotypes or IL-6 and mortality (adjusted for age, sex, CMV status and prevalent cancer). Table 4. Associations between immune cell phenotypes or IL-6 and mortality (adjusted for age, sex, CMV status and cardiovascular risk factors). Table 5. Associations between immune cell phenotypes or IL-6 and mortality (adjusted for age, sex, CMV status, prevalent cardiovascular disease, prevalent cancer, diabetes, HTN, use of lipid lowering medications, BMI and smoking status). Table 6. Associations between immune cell phenotypes or IL-6 and mortality for participants over 60 years of age. (adjusted for age, sex, CMV status, prevalent cardiovascular disease, prevalent cancer, diabetes, HTN, use of lipid lowering medications, BMI and smoking status). Table 7. Associations between immune cell phenotypes or IL-6 and mortality for participants over 60 years of age. (adjusted for age, sex and CMV status). Table 8. Associations between immune cell phenotypes or IL-6 and mortality for participants over 60 years of age. (adjusted for age, sex, CMV status and prevalent cancer). Table 9. Associations between immune cell phenotypes or IL-6 and mortality for participants over 60 years of age. (adjusted for age, sex, CMV status and cardiovascular risk factors). Table 10. Associations between immune cell phenotypes or IL-6 and mortality for participants with positive CMV status. (adjusted for age, sex, prevalent cardiovascular disease, prevalent cancer, diabetes, HTN, use of lipid lowering medications, BMI and smoking status). Table 11. Associations between immune cell phenotypes or IL-6 and mortality for participants with positive CMV status. (adjusted for age and sex). Table 12. Associations between immune cell phenotypes or IL-6 and mortality for participants with positive CMV status. (adjusted for age, sex and prevalent cancer). Table 13. Associations between immune cell phenotypes or IL-6 and mortality for participants with positive CMV status. (adjusted for age, sex and cardiovascular risk factors). Table 14. Associations between immune cell phenotypes or IL-6 and mortality. (adjusted for sex and CMV status). Table 15. Associations between immune cell phenotypes or IL-6 and mortality (adjusted for sex, CMV status, prevalent cardiovascular disease, prevalent cancer, diabetes, HTN, use of lipid lowering medications, body mass index (BMI) and smoking status). Table 16. Association of immune cell phenotypes with age adjusting for sex and CMV status covariates.